What is Boston Medical Sciences working on?

It is developing a non-invasive AI colorectal cancer screening system that combines virtual bowel cleansing AI with polyp detection AI.

Does the system require laxative preparation?

No. The system aims to enable colorectal CT exams without laxative use.

Can the product be sold or used now?

No. It is an unapproved investigational product in both Japan and the US, and cannot be sold or granted.

AI in HealthcareAI Business & IndustryPR TIMES (AI)22h agoNov 14, 2026, 01:00 JST

Global Brain co-leads new round in Boston Medical Sciences

Send on LINE

3 Key Points

What happened
Global Brain made an additional co-lead investment in Boston Medical Sciences (BMS) through the TAKANAWA GATEWAY Earth Benefit Fund, Meiji Yasuda Future Co-Creation Fund, GB9 Fund, TOHO Ventures and TMN100. The GB9, TOHO Ventures and TMN100 vehicles are new investments.
Why it matters
The backing gives BMS more funding to develop and clinically deploy its non-invasive AI colorectal cancer screening system, which aims to avoid the laxative preparation that currently deters patients from colonoscopy.

WHO IT HITSPatients who avoid colorectal cancer screening because of laxative preparation may gain access to a less burdensome option if BMS's system reaches clinical use, though the product remains unapproved in both Japan and the US.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Get these free every morning

Context & Analysis

Global Brain has invested in Boston Medical Sciences before, having announced investments through the Meiji Yasuda Future Co-Creation Fund in October 2024 and February 2025. This latest round, made through the TAKANAWA GATEWAY Earth Benefit Fund, Meiji Yasuda Future Co-Creation Fund, GB9 Fund, TOHO Ventures and TMN100, brings three new funds — GB9, TOHO Ventures and TMN100 — into the company for the first time. The firm cited BMS's management team of physicians, researchers and engineers, its AI technology for laxative-free screening, its FDA Breakthrough Device designation, and its research network including Harvard Medical School and Massachusetts General Hospital as reasons for the investment. BMS has also built research ties with 3D Imaging Research at Massachusetts General Hospital, the National Cancer Center Hospital in Japan, and the Tokushukai Group, where it began joint research on AI-assisted colorectal CT in June 2026. The system remains unapproved in both Japan and the US, so the new funding is aimed at moving it toward clinical implementation rather than immediate commercialization.

FAQ

What is Boston Medical Sciences working on?: It is developing a non-invasive AI colorectal cancer screening system that combines virtual bowel cleansing AI with polyp detection AI.
Does the system require laxative preparation?: No. The system aims to enable colorectal CT exams without laxative use.
Can the product be sold or used now?: No. It is an unapproved investigational product in both Japan and the US, and cannot be sold or granted.

PR TIMES (AI)Read Original Article

Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.